Investigators sought to determine whether a ctDNA-guided adjuvant atezolizumab dosing strategy was more cost-effective than a standard stage-based strategy for patients with MIBC.
The optimal adjuvant treatment approach for muscle-invasive bladder cancer (MIBC) remains unsettled. The IMvigor011 trial demonstrated that circulating tumor DNA (ctDNA)–guided adjuvant atezolizumab ...
Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.
The median disease-free survival was 9.9 months for the atezolizumab arm and 4.8 months for the placebo arm. In muscle-invasive bladder cancer (MIBC) patients, circulating tumor DNA (ctDNA)-guided, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results